Oct 20, 2017 Promising preliminary long-term data for WTX101 in Wilson Disease highlighted at The Liver Meeting® Read more
(WorldNews Health)

Oct 20, 2017 Wilson Therapeutics (publ) announced today that preliminary data from the ongoing extension part of the Phase 2 trial with WTX101 (bis-choline tetrathiomolybdate), an investigational oral first-in-class copper-protein binding agent for the treatment of patients with Wilson Disease, will be presented tomorrow at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington DC. The poster will be presented by Professor Michael Schilsky, Director of the Center for Excellence for Wilson Disease at Yale University Medical Center, tomorrow October 21 at 17:30-19:30 ET. Professor Michael Schilsky commented: `The data from the...